---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-093983"
form_type: "8-K/A"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2025-09-30T23:59:59+00:00"
generated_at: "2026-05-17T05:15:08.345926+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CorMedix files Melinta acquisition financials; Melinta 2024 revenue $120M, net loss $4.7M

## Summary
- Melinta 2024 total revenue $119.97M (product $106.3M) vs $105.6M in 2023; net loss narrowed to $4.7M from $36.0M.
- Cash and equivalents $49.8M at Dec 31, 2024; total assets $177.6M, notes payable $84.9M.
- CorMedix acquired Melinta on Aug 29, 2025 for undisclosed terms; Melinta markets seven anti-infective brands including BAXDELA, VABOMERE, ORBACTIV.

## SEC filing metadata
- accession: 0001213900-25-093983
- form_type: 8-K/A
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2025-09-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390025093983/0001213900-25-093983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390025093983/ea0258874-8ka1_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-093983
- JSON: https://secwatch.observer/filing/0001213900-25-093983.json
- Plain text: https://secwatch.observer/filing/0001213900-25-093983.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.